Based on our present results, patients with MM mimicking the molecular profile/behavior of LP-1 at any clinical evaluation point during the long-term clinical course of MM will be candidates for therapeutic regimens other than bortezomib. Here, RPLP1 is linked to Miyoshi myopathy.